Giuliana Amaddeo
A5079992976- Hepatocellular Carcinoma Treatment and Prognosis
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Liver Disease Diagnosis and Treatment
- Hepatitis B Virus Studies
- Hepatitis C virus research
- Liver Diseases and Immunity
- Cancer-related molecular mechanisms research
- RNA modifications and cancer
- Cancer Mechanisms and Therapy
- Liver Disease and Transplantation
- Liver physiology and pathology
- Cancer Genomics and Diagnostics
- Ferroptosis and cancer prognosis
- Organ Transplantation Techniques and Outcomes
- Cancer Immunotherapy and Biomarkers
- MicroRNA in disease regulation
- Colorectal Cancer Treatments and Studies
- Cancer, Hypoxia, and Metabolism
- Radiomics and Machine Learning in Medical Imaging
- Galectins and Cancer Biology
- Gallbladder and Bile Duct Disorders
- Pancreatic and Hepatic Oncology Research
- Peptidase Inhibition and Analysis
- MRI in cancer diagnosis
- Medical Imaging Techniques and Applications
Université Paris-Est Créteil
2016-2025
Assistance Publique – Hôpitaux de Paris
2016-2025
Inserm
2016-2025
Hôpitaux Universitaires Henri-Mondor
2017-2025
Institut Mondor de Recherche Biomédicale
2014-2025
Centre Hospitalier Universitaire Henri-Mondor
2015-2024
Hôpital Albert-Chenevier
2018-2024
Paris-Est Sup
2016-2024
Demos
2023
Biotherapy of Genetic Diseases, Inflammatory Disorders and Cancers
2020-2021
The prognosis of hepatocellular carcinoma (HCC) remains poor, with only one third patients eligible for curative treatments and very limited survival benefits the use sorafenib, current standard care advanced disease. Recently, agents targeting programmed death ligand 1 (PD-L1)/programmed receptor (PD-1) immune checkpoint were shown to display impressive antitumor activity in various solid or hematological malignancies, including HCC. PD-L1 immunohistochemical expression is thought represent...
Standardized and robust risk-stratification systems for patients with hepatocellular carcinoma (HCC) are required to improve therapeutic strategies investigate the benefits of adjuvant systemic therapies after curative resection/ablation.In this study, we used two deep-learning algorithms based on whole-slide digitized histological slides (whole-slide imaging; WSI) build models predicting survival HCC treated by surgical resection. Two independent series were investigated: a discovery set...
We recently identified a histological subtype of hepatocellular carcinoma (HCC), designated as "macrotrabecular-massive" (MTM-HCC) and associated with specific molecular features. In order to assess the clinical relevance this variant, we investigated its prognostic value in two large series patients HCC treated by either surgical resection or radiofrequency ablation (RFA). retrospectively included 237 samples 284 liver biopsies from RFA, respectively. Histological slides were reviewed...
Objective Infection by HBV is the main risk factor for hepatocellular carcinoma (HCC) worldwide. directly drives carcinogenesis through integrations in human genome. This study aimed to precisely characterise integrations, relation with viral and host genomics clinical features. Design A novel pipeline was set up perform capture on tumours non-tumour liver tissues from a French cohort of 177 patients mainly European African origins. Clonality each integration event determined localisation,...
To date, genomic analyses of hepatocellular carcinoma (HCC) have been limited to early stages obtained from liver resection. We aim describe the profiling HCC advanced stages. analyzed 801 720 patients (410 resections, 137 transplantations, 122 percutaneous ablations, and 52 noncurative) for 190 gene expressions 31 mutations. Forty-one 156 whole exome Barcelona Clinic Liver Cancer (BCLC) 0/A were by whole-exome sequencing. Genomic was correlated with tumor stages, clinical features,...
Abstract Bile duct injury (BDI) is a dangerous complication of cholecystectomy, with significant postoperative sequelae for the patient in terms morbidity, mortality, and long-term quality life. BDIs have an estimated incidence 0.4–1.5%, but considering number cholecystectomies performed worldwide, mostly by laparoscopy, surgeons must be prepared to manage this surgical challenge. Most are recognized either during procedure or immediate period. However, some may discovered later period,...
<h3>Background and aim</h3> Hepatocellular carcinoma (HCC) is the most common liver cancer. We characterised HCC associated with infection compared non-HBV-related to understand interactions between viral hepatocyte genomic alterations their relationships clinical features. <h3>Methods</h3> Frozen HBV (n=86) or (n=90) were collected in two French surgical departments. Viral characterisation was performed by sequencing <i>HBS</i> <i>HBX</i> genes quantifying DNA cccDNA. Nine screened for...
Abstract Cyclins A2 and E1 regulate the cell cycle by promoting S phase entry progression. Here, we identify a hepatocellular carcinoma (HCC) subgroup exhibiting cyclin activation through various mechanisms including hepatitis B virus (HBV) adeno-associated type 2 (AAV2) insertions, enhancer hijacking recurrent CCNA2 fusions. Cyclin or alterations define homogenous entity of aggressive HCC, mostly developed in non-cirrhotic patients, characterized transcriptional E2F ATR pathways high...
To evaluate whether hepatitis B virus (HBV) preS/S gene variability has any impact on serum surface antigen (HBsAg) levels and to analyze the replication capacity of naturally occurring variants, sera from 40 untreated patients with HBV-related chronic liver disease (hepatitis e [HBeAg]-positive, n = 11; HBeAg-negative, 29) were virologically characterized. Additionally, phenotypic analysis three different variant isolates (carrying a 183-nucleotide deletion within preS1 region, preS2 start...
Background The recently described "macrotrabecular-massive" (MTM) histologic subtype of hepatocellular carcinoma (HCC) (MTM-HCC) represents an aggressive form HCC and is associated with poor survival. Purpose To investigate whether preoperative MRI can help identify MTM-HCCs in patients HCC. Materials Methods This retrospective study included treated surgical resection between January 2008 February 2018 who underwent multiphase contrast material-enhanced MRI. Least absolute shrinkage...
Adeno-associated virus (AAV) is a defective mono-stranded DNA virus, endemic in human population (35%-80%). Recurrent clonal AAV2 insertions are associated with the pathogenesis of rare hepatocellular carcinoma (HCC) developed on normal liver. This study aimed to characterise natural history AAV infection liver and its consequence tumour development.Viral was quantified non-tumour tissues 1461 patients. Presence episomal form viral mRNA expression were analysed using DNAse/TaqMan-based assay...
Macrotrabecular-massive hepatocellular carcinoma (MTM-HCC) is a novel morphological subtype of HCC associated with early relapse after resection or percutaneous ablation, independently classical clinical and radiological prognostic factors. The aim the present study was to identify immunohistochemical markers MTM-HCC, ease its diagnosis implementation into practice.To potential biomarkers we first analyzed gene expression profiling data from Cancer Genome Atlas further selected two candidate...
•Age, sex, fibrosis and alcohol modulate liver telomere attrition.•Liver length associates with variable HCC clinical molecular subtypes.•HCC tumor is influenced by factors.•HCC cancer cells show actionable oncogenic addiction to TERT activation. Background & AimsTelomerase activation the earliest event in hepatocellular carcinoma (HCC) development. Thus, we aimed elucidate role of maintenance during carcinogenesis.MethodsTelomere was measured non-tumor tissues 1,502 patients (978 HCC)...
Regorafenib is one option for second-line treatment of hepatocellular carcinoma (HCC), improving overall survival (OS) sorafenib-tolerant patients who develop progression. We aim to evaluate the safety and outcomes regorafenib as HCC recurrence after liver transplantation (LT). This a retrospective, multicenter, international study including regorafenib-treated LT (2015-2018), with analysis baseline characteristics evolutionary events during sorafenib/regorafenib treatment. Twenty-eight (57...
The impact of tertiary lymphoid structures (TLS) in hepatocellular carcinoma (HCC) progression is being extensively investigated. However, their presence during the early steps human liver carcinogenesis remains unknown. We thus aimed to determine whether TLS are induced preneoplastic/early hepatic lesions (EHL), and they associated with a particular immune profile.A series 127 EHLs (low/high-grade dysplastic nodules, HCC, small progressed HCC) was included study. TLSs were investigated by...
Interim analysis of the DOSISPHERE-01 study demonstrated a strong improvement in response and overall survival (OS) on using <sup>90</sup>Y-loaded glass microspheres with personalized dosimetry compared standard patients nonoperable locally advanced hepatocellular carcinoma. This report sought to provide long-term OS. <b>Methods:</b> In this phase II (ClinicalTrials.gov identifier NCT02582034), treatment was randomly assigned (1:1) goal deliver either at least 205 Gy (if possible >250–300...
Patients affected by hepatocellular carcinoma (HCC) represent a vulnerable population during the COVID-19 pandemic and may suffer from altered allocation of healthcare resources. The aim this study was to determine impact on management patients with HCC within 6 referral centres in metropolitan area Paris, France.We performed multicentre, retrospective, cross-sectional first weeks (exposed group), compared same period 2019 (unexposed group). We included all discussed multidisciplinary tumour...